Rise In Generics Takes A Toll On Rite Aid Corporation (NYSE:RAD)’s Pharmacy Sales

Drugstore operator, Rite Aid Corporation (NYSE:RAD), managed to post sales improvement last month compared to the same month a year earlier. However, sales in the pharmacy segment were down by more than a percentage point in the month because of the impact from new generic drugs. Overall, drugstore operators have continued to show their appetite for pharmacy-benefits managers with RAD announcing a deal to buy EnvisionRx.

Technical analyst have identified strong buy signals in RAD.

Sales up YoY

February 2015 total drugstore sales at Rite Aid Corporation (NYSE:RAD) were up 1.7% to $2.56 billion. That was higher than $2.51 billion in the same month in 2014. Coming to same-store sales, Rite Aid registered 3.3% uptick in sale while pharmacy sales were up 4.1%. The front-end sales also rose 1.6%.

While last month’s sales rose against a year ago, the growth was slower than in the prior month. Overall drugstore sales in January rose 4.3% and same-store sales went up by 4.8%.

As for the pharmacy sales, Rite Aid Corporation (NYSE:RAD) noted that sales declined 1.44%, primarily due to the impact of new generic drugs.

Acquisition into benefits services

Meanwhile, Rite Aid Corporation (NYSE:RAD) is moving to match its larger rival CVS Health Corp (NYSE:CVS) with the acquisition of into the pharmacy-benefits services. The company announced a $2 billion buyout deal for EnvisionRx, a step that the management of Rite Aid said would enable them to expand their pharmacy offering. Additionally, RAD expects the acquisition to enable to deliver cost-effective solutions to health plans and employers.

The financial benefits of acquiring EnvisionRx are also obvious. The pharmacy-benefits manager generates annual sales of about $5 billion and earns about $160 million in EBITDA. The acquisition of EnvisionRx is expected to make Rite Aid Corporation (NYSE:RAD) the third-largest U.S. benefits provider. The company’s income is also expected to get a boost from the acquisition.

Push for lower drug prices

Express Scripts Holding Company (NASDAQ:ESRX) remains the industry heavyweight in the benefits services. Both CVS and Express Scripts have been heaping pressure on drug companies to lower prices. Their latest targets are the manufacturers of a new class of expensive drugs known as biologics.

 

Enter Email Here

START HERE: Get Your
FREE Report On This Stock

To reeive our FREE investing report and weekly alerts, enter your information below!

Your privacy is important to us. We’ll never share your information.

 

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

https://www.USmarketsDaily.com/disclaimer

 











 

Erica

Erica

Erica is a graduate of New York University's school of Journalism. She joined US Markets Daily as a general assignment reporter in January of 2008.